guest ::
| Home > Publications database > Genetically Determined Telomere Length Is Associated with Pancreatic Neuroendocrine Neoplasms Onset. > print |
| Home > Publications database > Genetically Determined Telomere Length Is Associated with Pancreatic Neuroendocrine Neoplasms Onset. > print |
| 001 | 182838 | ||
| 005 | 20240229145733.0 | ||
| 024 | 7 | _ | |a 10.1159/000524659 |2 doi |
| 024 | 7 | _ | |a pmid:35472852 |2 pmid |
| 024 | 7 | _ | |a 0028-3835 |2 ISSN |
| 024 | 7 | _ | |a 1423-0194 |2 ISSN |
| 024 | 7 | _ | |a altmetric:127366751 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2022-02965 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Gentiluomo, Manuel |b 0 |
| 245 | _ | _ | |a Genetically Determined Telomere Length Is Associated with Pancreatic Neuroendocrine Neoplasms Onset. |
| 260 | _ | _ | |a Basel |c 2022 |b Karger |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1669814678_4797 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Telomere length (TL) is a potential indicator of cancer predisposition; however, the multitude of techniques used to measure it causes the results to be heterogeneous and, in some cases, controversial. In the last years, several studies adopted a strategy based on TL-associated genetic variants to generate a polygenic score, often referred as teloscore, used in lieu of direct TL measurement. For pancreatic neuroendocrine neoplasms (PanNEN), this strategy has not been attempted yet.A teloscore was generated using 11 SNPs (NAF1-rs7675998, ZNF676-rs409627, TERC-rs10936599, CTC1-rs3027234, PXK-rs6772228, DHX35-rs6028466, OBFC1-rs9420907, ZNF208-rs8105767, ACYP2-rs11125529, TERT-rs2736100, and ZBTB46-rs755017), and 291 PanNEN cases and 1,686 controls collected by the PANcreatic Disease ReseArch (PANDoRA) consortium were genotyped to analyse the association of the teloscore and its individual SNPs with the risk of developing PanNEN.An association between genetically determined long telomeres and the risk of developing PanNEN (OR = 1.99, CI: 1.33-2.98, p = 0.0008) for highest versus median (third) quintile was observed. In addition, two novel SNPs associated with PanNEN risk were identified: ZNF676-rs409627 (ORC/C_vs_G/G = 2.27, CI: 1.58-3.27, p = 8.80 × 10-6) and TERT-rs2736100 (ORC/A_vs_C/C = 2.03, CI: 1.42-2.91, p = 1.06 × 10-4).In conclusion, this study provides for the first time a clear indication of the association between long genetically determined telomeres and increased risk of developing PanNEN. |
| 536 | _ | _ | |a 313 - Krebsrisikofaktoren und Prävention (POF4-313) |0 G:(DE-HGF)POF4-313 |c POF4-313 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a Pancreatic neuroendocrine neoplasms |2 Other |
| 650 | _ | 7 | |a Polygenic risk score |2 Other |
| 650 | _ | 7 | |a Risk |2 Other |
| 650 | _ | 7 | |a Teloscore |2 Other |
| 650 | _ | 7 | |a ACYP2 protein, human |0 EC 3.6.1.7 |2 NLM Chemicals |
| 650 | _ | 7 | |a Acid Anhydride Hydrolases |0 EC 3.6.- |2 NLM Chemicals |
| 650 | _ | 2 | |a Humans |2 MeSH |
| 650 | _ | 2 | |a Genome-Wide Association Study |2 MeSH |
| 650 | _ | 2 | |a Case-Control Studies |2 MeSH |
| 650 | _ | 2 | |a Telomere: genetics |2 MeSH |
| 650 | _ | 2 | |a Polymorphism, Single Nucleotide: genetics |2 MeSH |
| 650 | _ | 2 | |a Neoplasms |2 MeSH |
| 650 | _ | 2 | |a Pancreatic Neoplasms: genetics |2 MeSH |
| 650 | _ | 2 | |a Acid Anhydride Hydrolases: genetics |2 MeSH |
| 700 | 1 | _ | |a Capurso, Gabriele |b 1 |
| 700 | 1 | _ | |a Morelli, Luca |b 2 |
| 700 | 1 | _ | |a Ermini, Stefano |b 3 |
| 700 | 1 | _ | |a Pasquali, Claudio |b 4 |
| 700 | 1 | _ | |a Latiano, Anna |b 5 |
| 700 | 1 | _ | |a Tavano, Francesca |b 6 |
| 700 | 1 | _ | |a Greenhalf, William |b 7 |
| 700 | 1 | _ | |a Milanetto, Anna Caterina |b 8 |
| 700 | 1 | _ | |a Landi, Stefano |b 9 |
| 700 | 1 | _ | |a Roth, Susanne |b 10 |
| 700 | 1 | _ | |a Malecka-Wojciesko, Ewa |b 11 |
| 700 | 1 | _ | |a Costello, Eithne |b 12 |
| 700 | 1 | _ | |a Jamroziak, Krzysztof |b 13 |
| 700 | 1 | _ | |a Perri, Francesco |b 14 |
| 700 | 1 | _ | |a Boggi, Ugo |b 15 |
| 700 | 1 | _ | |a Basso, Daniela |b 16 |
| 700 | 1 | _ | |a Farinati, Fabio |b 17 |
| 700 | 1 | _ | |a Kaaks, Rudolf |0 P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a |b 18 |u dkfz |
| 700 | 1 | _ | |a Vanella, Giuseppe |b 19 |
| 700 | 1 | _ | |a Gais Zurcher, Anna-Lea J |b 20 |
| 700 | 1 | _ | |a Archibugi, Livia |b 21 |
| 700 | 1 | _ | |a Lawlor, Rita T |b 22 |
| 700 | 1 | _ | |a Canzian, Federico |0 P:(DE-He78)5323704270b6393dcea70186ffd86bca |b 23 |u dkfz |
| 700 | 1 | _ | |a Campa, Daniele |b 24 |
| 773 | _ | _ | |a 10.1159/000524659 |g Vol. 112, no. 12, p. 1168 - 1176 |0 PERI:(DE-600)1483028-0 |n 12 |p 1168 - 1176 |t Neuroendocrinology |v 112 |y 2022 |x 0028-3835 |
| 909 | C | O | |o oai:inrepo02.dkfz.de:182838 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 18 |6 P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 23 |6 P:(DE-He78)5323704270b6393dcea70186ffd86bca |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-313 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Krebsrisikofaktoren und Prävention |x 0 |
| 914 | 1 | _ | |y 2022 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2021-02-03 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2021-02-03 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2021-02-03 |
| 915 | _ | _ | |a National-Konsortium |0 StatID:(DE-HGF)0430 |2 StatID |d 2022-11-19 |w ger |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b NEUROENDOCRINOLOGY : 2021 |d 2022-11-19 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2022-11-19 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2022-11-19 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2022-11-19 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2022-11-19 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2022-11-19 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2022-11-19 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2022-11-19 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2022-11-19 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b NEUROENDOCRINOLOGY : 2021 |d 2022-11-19 |
| 920 | 1 | _ | |0 I:(DE-He78)C020-20160331 |k C020 |l C020 Epidemiologie von Krebs |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)C055-20160331 |k C055 |l C055 Genomische Epidemiologie |x 1 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)C020-20160331 |
| 980 | _ | _ | |a I:(DE-He78)C055-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|